Your Path to Successful Market Access
We combine regulatory expertise with market insight and strategy.
Dr. Carolina Diaz
Compliance Specialist / Consultant
What does Market Access mean in the pharmaceutical industry?
Market Access in the pharmaceutical industry goes far beyond the launch of a new drug. The goal is not only to secure regulatory approval for innovative medicines and therapies, but also to ensure that they are accessible to patients, physicians, and other key stakeholders within the healthcare system. This includes comprehensive market analyses, strategic pricing negotiations, reimbursement decisions, and the development of effective supply and distribution structures.
In the highly regulated pharmaceutical environment, the success of a product largely depends on how effectively it is integrated into national or international healthcare systems. In practice, this requires companies to begin strategic Market Access planning early in the product development process, aligning clinical, regulatory, and economic strategies as efficiently as possible.
This process includes analyzing potential target markets, assessing regulatory requirements across different countries (for example, CONITEC in Brazil, NICE in the United Kingdom, or the National Healthcare Security Administration in China), preparing robust dossiers for health technology assessments, and getting ready for price and reimbursement negotiations with payers. Equally important are the structures of healthcare systems and the priorities of stakeholders such as patients, healthcare professionals, key opinion leaders, medical societies, and health insurers.
A structured and well-designed Market Access strategy bridges the gap between research and real-world patient care. It ensures that scientific innovation is translated into therapies that reach the market in a timely, targeted, and sustainable manner.
The goal of Market Access: New medicines should not only achieve regulatory approval, but also be economically viable, reimbursable, and available to the right patients within the appropriate treatment window.
The entire process is divided into four interrelated core phases:
Regulatory Approval
Even before the approval process begins, careful planning is essential. This includes defining target groups and developing strategies to effectively reach them. Regulatory requirements vary depending on the product and market and must be fully met.
Pricing
Product pricing is influenced by development costs, clinical benefit, degree of innovation, and market demand. Establishing the right price is critical for long-term success.
Reimbursement
In both the pharmaceutical and medical device sectors, companies must negotiate with public and private payers to secure reimbursement and ensure access for patients.
Availability
Once approved and reimbursed, a product must also be physically available, for example in pharmacies, hospitals, or through specialized distribution channels. For complex therapies, early logistical planning is crucial.
Market Analysis & Target Market Assessment
A successful Market Access strategy begins with selecting the right target markets. Not every market offers the same opportunities, as regulatory requirements, reimbursement systems, healthcare structures, and competitive conditions differ significantly between countries. A robust market analysis therefore forms the foundation for all strategic decisions throughout the Market Access process.
We support companies in evaluating both local and international market opportunities and identifying potential risks. Our approach helps prioritize the markets best suited to your product, from regulatory, economic, and healthcare policy perspectives, while maximizing the chances of successful entry.
Our methodology combines regulatory expertise, health economics knowledge, and data-driven market analysis. We consider not only the requirements of regulatory authorities, but also reimbursement practices, healthcare delivery structures, stakeholder environments, and competitive dynamics.
Our services in Market Analysis & Target Market Assessment include:
- Identification of strategic target markets: Analysis of your product portfolio, competitive landscape, and available resources to define prioritized markets and establish an optimal go-to-market strategy.
- Systematic market analysis: Examination of healthcare systems, regulatory frameworks, pricing levels, distribution channels, care pathways, and market entry barriers.
- Market access assessment: Evaluation of potential access hurdles, positioning opportunities, and reimbursement-relevant factors to ensure economic viability.
With this structured approach, we provide a solid decision-making basis for achieving regulatory compliance, economic sustainability, and long-term Market Access success.
Care Pathway Analysis
Meeting regulatory requirements is only one step toward successful Market Access. Equally important is understanding how a medicine will be integrated into clinical practice, care pathways, and the overall patient journey. This requires a precise analysis of the complete patient trajectory, which is often complex and shaped by the specific healthcare system.
The care pathway covers all steps, from diagnosis and treatment decisions to therapy administration, adherence, and follow-up. Each stage involves specific stakeholders, processes, and potential access barriers that influence real-world therapy uptake. The analysis not only examines existing procedures but also highlights unmet or insufficiently addressed healthcare needs.
We conduct detailed pathway analyses to uncover structural weaknesses, decision-making obstacles, and practical barriers. Our approach combines qualitative and quantitative methods including stakeholder interviews, surveys, workshops, and healthcare data evaluation. Based on these insights, we help companies identify and address access barriers at an early stage. A deep understanding of clinical workflows, real-world care settings, and unmet medical needs strengthens positioning in health technology assessments, increases reimbursement potential, and accelerates market entry.
Our Care Pathway Analyses provide answers to key questions
Who makes the critical decisions along the care pathway
We map the roles of general practitioners, specialists, hospitals, decision-makers, payers, and institutions such as the G-BA, CONITEC, or NICE
Which stakeholders are involved
Beyond healthcare professionals, these include patients, providers, payers, policymakers, and relevant organizations. The composition varies by healthcare system, therapeutic area, and region.
Where are the main barriers along the care pathway
These may include lack of reimbursement, limited affordability, insufficient disease awareness, lack of training, or unavailability of diagnostic procedures.
How does the care pathway influence product positioning
Targeted analysis can enhance product visibility and acceptance by engaging relevant audiences early and ensuring integration into real-world clinical practice.
A Care Pathway Analysis provides a solid foundation for strategic Market Access planning from both regulatory and healthcare perspectives. It enables companies to address barriers at an early stage, target unmet needs, and develop concrete measures creating the conditions for effective, sustainable, and patient-centered Market Access.
Your Direct Contact
I am happy to assist you personally.